Loading company…
Mimetogen Pharmaceuticals develops synthetic neurotrophin mimetics for ocular conditions, including dry eye disease.
Mimetogen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing synthetic neurotrophin mimetics for ocular conditions. Its lead product, tavilermide, is being evaluated for dry eye disease and was in multi-center Phase 3 trials. Founded in 2004 and based in Montreal, Canada, the company raised USD 800,000 from Medwell Capital in July 2013.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in